Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing

Pain

Volumn 142, Issue 1-2, 2009, Pages 116-126

  Cottrell, Jessica A ^a   Meyenhofer, Markus ^a   Medicherla, Satyanarayana ^b   Higgins, Linda ^b   O'Connor, J Patrick ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b SCIOS INC   (United States)

Author keywords

Analgesia; Animal model; Bone regeneration; Fracture healing; p38 kinase; Pain management; Pain model

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHINE; PARACETAMOL; SCIO 469;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE PAIN; BONE REGENERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FRACTURE HEALING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOGRAPHY; RAT; TORSION;

ANALGESICS; ANIMALS; AREA UNDER CURVE; BIOPHYSICS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; FRACTURE HEALING; FRACTURES, BONE; INDOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PAIN; PAIN MEASUREMENT; RADIOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TORSION, MECHANICAL; WEIGHT-BEARING;

EID: 60249083515     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.12.019     Document Type: Article

References (66)

1. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279 (1996) 1453-1461
2. Bannwarth B., Netter P., Lapicque F., Gillet P., Pere P., Boccard E., et al. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. Br J Clin Pharmacol 34 (1992) 79-81
3. Bergenstock M., Min W., Simon A.M., Sabatino C., and O'Connor J.P. A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats. J Orthop Trauma 19 (2005) 717-723
4. Brown K.M., Saunders M.M., Kirsch T., Donahue H.J., and Reid J.S. Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg Am 86-A (2004) 116-123
5. Burd T.A., Hughes M.S., and Anglen J.O. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 85-B (2003) 700-705
6. Burian M., and Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 107 (2005) 139-154
7. Campbell J.N., and Meyer R.A. Mechanisms of neuropathic pain. Neuron 52 (2006) 77-92
8. Camuso M.R. Far-forward fracture stabilization: external fixation versus splinting. J Am Acad Orthop Surg 14 (2006) S118-123
9. Ciceri P., Zhang Y., Shaffer A.F., Leahy K.M., Woerner M.B., Smith W.G., et al. Pharmacology of celecoxib in rat brain after kainate administration. J Pharmacol Exp Ther 302 (2002) 846-852
10. de Mos M., de Bruijn A.G., Huygen F.J., Dieleman J.P., Stricker B.H., and Sturkenboom M.C. The incidence of complex regional pain syndrome: a population-based study. Pain 129 (2007) 12-20
11. DeLeo J.A. Basic science of pain. J Bone Joint Surg Am 88 (2006) 58-62
12. Einhorn T.A. Do inhibitors of cyclooxygenase-2 impair bone healing?. J Bone Miner Res 17 (2002) 977-978
13. Ekman E.F., and Koman L.A. Acute pain following musculoskeletal injuries and orthopaedic surgery: mechanisms and management. Instr Course Lect 54 (2005) 21-33
14. Fijen J.W., Tulleken J.E., Kobold A.C., de Boer P., van der Werf T.S., Ligtenberg J.J., et al. Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med 30 (2002) 841-845
15. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., and Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88 (2003) 873-884
16. Gerstenfeld L.C., Thiede M., Seibert K., Mielke C., Phippard D., Svagr B., et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orth Res 21 (2003) 670-675
17. Giannoudis P.V., MacDonald D.A., Matthews S.J., Smith R.M., Furlong A.J., and De Boer P. Nonunion of the femoral diaphysis: the influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br 82-B (2000) 655-658
18. Graham G.G., and Scott K.F. Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology 11 (2003) 401-413
19. Guo T.Z., Offley S.C., Boyd E.A., Jacobs C.R., and Kingery W.S. Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I. Pain 108 (2004) 95-107
20. Haegerstam G.A. Pathophysiology of bone pain: a review. Acta Orthop Scand 72 (2001) 308-317
21. Harvey R.J., Depner U.B., Wässle H., Ahmadi S., Heindl C., Reinold H., et al. GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 304 (2004) 884-887
22. Hedequist D., Starr A.J., Wilson P., and Walker J. Early versus delayed stabilization of pediatric femur fractures: analysis of 387 patients. J Orthop Trauma 13 (1999) 490-493
23. Hideshima T., Podar K., Chauhan D., Ishitsuka K., Mitsiades C., Tai Y.T., et al. P38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23 (2004) 8766-8776
24. Hukkanen M., Konttinen Y.T., Rees R.G., Santavirta S., Terenghi G., and Polak J.M. Distribution of nerve endings and sensory neuropeptides in rat synovium, meniscus and bone. Int J Tissue React 14 (1992) 1-10
25. Hukkanen M., Konttinen Y.T., Santavirta S., Paavolainen P., Gu X.H., Terenghi G., et al. Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling. Neuroscience 54 (1993) 969-979
26. Jackson J.R., Bolognese B., Hillegass L., Kassis S., Adams J., Griswold D.E., et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 284 (1998) 687-692
27. Ji R.R. Peripheral and central mechanisms of inflammatory pain, with emphasis on MAP kinases. Curr Drug Targets Inflamm Allergy 3 (2004) 299-303
28. Jimenez-Andrade J.M., Martin C.D., Koewler N.J., Freeman K.T., Sullivan L.J., Halvorson K.G., et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain 133 (2007) 183-196
29. Kanjhan R. Opioids and pain. Clin Exp Pharmacol Physiol 22 (1995) 397-403
30. Karani R., and Meier D.E. Systemic pharmacologic postoperative pain management in the geriatric orthopaedic patient. Clin Orthop Relat Res (2004) 26-34
31. Koewler N.J., Freeman K.T., Buus R.J., Herrera M.B., Jimenez-Andrade J.M., Ghilardi J.R., et al. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J Bone Miner Res 22 (2007) 1732-1742
32. Koppelman B., Webb H.K., Medicherla S., Almirez R., Feng Y., Chavez J.C., et al. Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase. Pharmacology 81 (2008) 204-220
33. Krischak G.D., Augat P., Sorg T., Blakytny R., Kinzl L., Claes L., et al. Effects of diclofenac on periosteal callus maturation in osteotomy healing in an animal model. Arch Orthop Trauma Surg 127 (2007) 3-9
34. Lee M.R., and Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 12 (2005) 2979-2994
35. Lee Y.S., Kim H., Brahim J.S., Rowan J., Lee G., and Dionne R.A. Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain 129 (2007) 279-286
36. Levine J.D., Fields H.L., and Basbaum A.I. Peptides and the primary afferent nociceptor. J Neurosci 13 (1993) 2273-2286
37. Lim M.Y., Wang H., Kapoun A.M., O'Connell M., O'Young G., Brauer H.A., et al. P38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol 37 (2004) 1111-1114
38. Masferrer J.L., Isakson P.C., and Seibert K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 25 (1996) 363-372
39. Medhurst S.J., Walker K., Bowes M., Kidd B.L., Glatt M., Muller M., et al. A rat model of bone cancer pain. Pain 96 (2002) 129-140
40. Medicherla S., Ma J.Y., Mangadu R., Jiang Y., Zhao J.J., Almirez R., et al. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 318 (2006) 132-141
41. Mitchell J.A., and Warner T.D. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128 (1999) 1121-1132
42. Mullis K.B., Perry D.C., Finn A.M., Stafford B., and Sadee W. Morphine persistence in rat brain and serum after single doses. J Pharmacol Exp Ther 208 (1979) 228-231
43. Nikas S.N., and Drosos A.A. SCIO-469 Scios Inc. Curr Opin Investig Drugs 5 (2004) 1205-1212
44. Perez-Castrillon J.L., Olmos J.M., Gomez J.J., Barrallo A., Riancho J.A., Perera L., et al. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 72 (2000) 187-194
45. Petrizzi L., Mariscoli M., Valbonetti L., Varasano V., Langhoff J.D., and Von Rechenberg B. Preliminary study on the effect of parenteral naloxone, alone and in association with calcium gluconate, on bone healing in an ovine "drill hole" model system. BMC Musculoskelet Disord 8 (2007) 43
46. Pichereau C. Vioxx lifting the veil on the dark side of the pharmaceutical industry. Eur BioPharm Rev Spring (2005) 35-38
47. Plomp G.J., Maes R.A., and van Ree J.M. Disposition of morphine in rat brain: relationship to biological activity. J Pharmacol Exp Ther 217 (1981) 181-188
48. Portanova J.P., Zhang Y., Anderson G.D., Hauser S.D., Masferrer J.L., Seibert K., et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 184 (1996) 883-891
49. Rainsford K.D. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 107 (1999) 27S-36S
50. Raskin J.B. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 106 (1999) 3S-12S
51. Rø J., Sudmann E., and Marton P.F. Effect of indomethacin on fracture healing in rats. Acta Orthop Scand 47 (1976) 588-599
52. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S., et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410 (2001) 471-475
53. Santy J., and Mackintosh C. A phenomenological study of pain following fractured shaft of femur. J Clin Nurs 10 (2001) 521-527
54. Schieven G.L. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 5 (2005) 921-928
55. Schug S.A., Garrett W.R., and Gillespie G. Opioid and non-opioid analgesics. Best Pract Res Clin Anaesthesiol 17 (2003) 91-110
56. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91 (1994) 12013-12017
57. Simon A.M., Manigrasso M.B., and O'Connor J.P. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17 (2002) 963-976
58. Simon A.M., and O'Connor J.P. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am 89 (2007) 500-511
59. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271 (1996) 33157-33160
60. Sudmann E., Dregelid E., Bessesen A., and Mørland J. Inhibition of fracture healing by indomethacin in rats. Eur J Clin Invest 9 (1979) 333-339
61. Svensson C.I., Hua X.Y., Protter A.A., Powell H.C., and Yaksh T.L. Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. Neuroreport 14 (2003) 1153-1157
62. Svensson C.I., Marsala M., Westerlund A., Calcutt N.A., Campana W.M., Freshwater J.D., et al. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 86 (2003) 1534-1544
63. Sweitzer S.M., Medicherla S., Almirez R., Dugar S., Chakravarty S., Shumilla J.A., et al. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 109 (2004) 409-419
64. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
65. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiological foundations and clinical implications. Am J Med 106 (1999) 13S-24S
66. Zeilhofer H.U. Prostanoids in nociception and pain. Biochem Pharmacol 73 (2007) 165-174